Drug firm Wockhardt on Wednesday reported a consolidated net loss of Rs 16 crore for the second quarter ended September 30, ...

Wockhardt’s Q2 loss narrowed to ₹16 crore from ₹73 crore a year earlier, bolstered by a 7.4% revenue rise and expanded ...

Shares of Wockhardt ended higher by nearly 2% on the back of better results for the September quarter, after the pharma major ...

Through this QIP, Wockhardt said it aims to strengthen its capital structure, possibly funding growth initiatives or reducing ...

Wockhardt's equity dilution is pegged at 5.57% of post-issue paid up share capital, according to the term sheet.

Wockhardt shares have soared to an 8-year high of Rs 1,212.55, reflecting a remarkable 384% increase since November 10, 2023.

Wockhardt has been a wealth destroyer as its shares have underperformed Nifty 50 by over 150% over the last 10 years. However ...

Wockhardt's Q2 net loss shrinks to Rs 16 cr, with revenue reaching Rs 809 cr. Read about the company's financial performance and stock updates.

Shares of Wockhardt Ltd. will be in focus on Thursday as the drug manufacturer's Capital Raising Committee has approved the launch of its Qualified Institutional Placement (QIP), the company said in ...

Welcome to ET Prime Sunday edition. Over the past week, we have kept you up to speed with our deep dives and insightful pieces across sectors, from pharma, markets, tech to consumer and auto. Heres a ...

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.